The FDA approved Ultragenyx’s gene therapy Fayuvi (rebisufligene etisparvovec) for Sanfilippo syndrome type A, giving the rare pediatric disease its first disease-modifying treatment. The one-time AAV-based therapy is intended to restore SGSH function, reducing heparan sulfate buildup and targeting underlying disease biology rather than symptoms.